TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

Rhea-AI Summary

On September 29, 2020, TCR² Therapeutics Inc. (Nasdaq: TCRR) announced its management's participation in a fireside chat at the Jefferies Cell Therapy Virtual Summit on October 5, 2020, at 2:00 PM ET. This event will utilize a virtual platform, with a live webcast available on the Company’s Investors page and an archived replay accessible for at least 30 days post-presentation.

TCR² Therapeutics focuses on innovative T cell therapies for various cancers, with ongoing Phase 1/2 clinical trials for its lead candidates, TC-210 and TC-110.

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Monday, October 5, 2020 at 2:00pm E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at https://investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What is the date and time of TCRR's participation in the Jefferies Cell Therapy Virtual Summit?

TCRR will participate in the Jefferies Cell Therapy Virtual Summit on October 5, 2020, at 2:00 PM ET.

Where can I watch the live webcast of TCRR's presentation at the summit?

The live webcast of TCRR's presentation can be watched on the Investors page of the Company’s website.

What are the lead product candidates of TCRR currently in clinical trials?

The lead product candidates of TCRR in clinical trials are TC-210 for solid tumors and TC-110 for hematological malignancies.

How long will the archived replay of TCRR's presentation be available?

The archived replay of TCRR's presentation will be available for at least 30 days following the event.

What is the focus of TCRR's therapies?

TCRR focuses on developing novel T cell therapies for patients suffering from cancer, including solid tumors and hematological malignancies.